skip to main content
Give

M. Nasir Uddin

M. Nasir Uddin
M. Nasir Uddin, PhD, FAHA

Research Associate Professor

Contact

Medical Physiology
8447 John Sharp Parkway
Bryan, TX 77807
uddin65@tamu.edu

Education and Training

  • University of Dhaka, Bangladesh , B.Sc. (Hons) and M.Sc. in Biochemistry and Molecular Biology, 1988 & 1990
  • Gifu University, Gifu, Japan , PhD in Molecular Biology, 2000
  • Gifu University, Japan, Postdoctoral Fellow: Japan Society for Promotion of Science in Molecular Medicine, 2003-2005
  • Texas A&M Health Science Center College of Medicine and Baylor Scott & White Healthcare, Temple, Texas, USA in Hypertension in Pregnancy, Postdoctoral Research Associate, Assistant Research Scientist: , 2006-2010

Research Interests

  • Preeclampsia (preE) is a systemic and hypertensive pregnancy disorder, which occurs in 3 to 10% of all gestations—accounting for approximately 60,000 maternal deaths per year worldwide. PreE is characterized by the de novo onset of hypertension and proteinuria in pregnancy. The triggers of this condition remain elusive, and pathogenic mechanisms remain ambiguous, resulting in a failure to develop specific screening, preventive, and treatment strategies. Dr. Uddin’s lab focuses on translational research in maternal fetal medicine, especially hypertension during pregnancy. The long-term goal of his lab is to determine the pathogenesis and molecular signaling in hypertension during pregnancy (preE). The potential significance of his research is that successful completion may identify molecular therapeutic targets may be identified to effectively treat preE. He is using animal models (rodents and small monkey species), several human cell lines, and patients for his research.
  • Ovarian cancer remains a leading cause of cancer death among women, with poor five-year survival. Platinum compounds are the current standard of care, yet many patients develop resistance. Metastasis of primary tumors is the cause of death in most patients. Dr. Uddin’s lab has identified a novel inhibitor of tumor cell migration and metastasis which will be effective in preventing metastasis in advanced ovarian cancer.

Representative Publications

Mohamed S, Kundysek V, Vora N, Govande V, Raza R, Uddin MN. Diabetic pregnancy: A literature review of maternal and neonatal adverse outcomes. International Journal of Reproductive BioMedicine. 2025; Volume 23, Issue no. 2, https://doi.org/10.18502/24–67-7 (R)

2. Pantho AF, Zaman M, Afroze SH, Wages JM, Yu B, Larrick JW, Kuehl TJ, Vora N, Uddin MN. Neutralization of Marinobufagenin Demonstrates Efficacy In Vitro and In Vivo in Models of Pre-Eclampsia. Biomedicines. 2025; 13(4):782. https://doi.org/10.3390/biomedicines13040782.

 

3. Pantho AF, Zaman M, Afroze SH, Wages JM, Yu B, Larrick JW, Kuehl TJ, Vora N, Uddin MN. Neutralization of Marinobufagenin Demonstrates Efficacy In Vitro and In Vivo in Models of Pre-Eclampsia. Biomedicines. 2025; 13(4):782. https://doi.org/10.3390/biomedicines13040782.

4. Pantho AF, Mohamed S, Govande JV, Rane R, Vora N, Kelso KR, Kuehl TJ, Lindheim SR, Uddin MN. Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. 2024 Sep 13;13(18):1534. doi: 10.3390/cells13181534. PMID: 39329718; PMCID: PMC11430553.

5. Ark M, Uddin MN. Editorial: Cellular senescence in physiology and pathophysiology. Front Physiol. 2023 Mar 22;14:1173284. doi: 10.3389/fphys.2023.1173284. PMID: 37035657; PMCID: PMC10073689.

6. Vora N, Kalagiri RR, Shetty K, Mustafa Y, Kundysek W, Raju M, Govande V, Beeram M, Uddin MN. Comparison of clinical outcomes and biochemical markers in normal and preeclamptic pregnancies: a prospective cohort study. Proc (Bayl Univ Med Cent). 2023 Jun 22;36(5):572-577. doi: 10.1080/08998280.2023.2223449. PMID: 37614853; PMCID: PMC10443954.

7. Colόn NS, Pantho AF, Afroze SH, Ashraf AHMZ, Akter R, Kuehl TJ, Uddin MN. Reduced urinary angiotensinogen excretion in preeclampsia. Pregnancy Hypertens. 2022 Mar;27:1-5. doi: 10.1016/j.preghy.2021.10.012. Epub 2021 Nov 5. PMID: 34798372.

8. Horvat D, Afroze SH, Cromer WE, Pantho AF, Ashraf AHMZ, Kuehl TJ, Zawieja DC, Uddin MN. Cartiotonic steroids affect monolayer permeability in lymphatic endothelial cells. Mol Cell Biochem. 2021 Aug;476(8):3207-3213. doi: 10.1007/s11010-021-04147-9. Epub 2021 Apr 18.PMID: 33866492

9. N. Vora, R. Kalagiri, L. Mallett, J, Oh, U. Wajid, S. Munir, N. Colon, V. Raju, M. Beeram and Uddin MN. Proteomics and Metabolomics in Pregnancy—An Overview. Obstetrical & Gynecological Survey. 74(2):111–125, FEB 2019.

10. Syeda H. Afroze, Chander Peddaboina, Anthony B. McDowell, A H M Zuberi Ashraf, Timothy C. McCormick, M. Karen Newell-Rogers, David C. Zawieja, Thomas J. Kuehl, Uddin MN. Differential effects of in vitro treatment with cinobufotalin on three types of ovarian cancer cells. Anticancer Res. 2018 Oct;38(10):5717-5724.doi: 10.21873/anticanres.12909.

11. A H M Zuberi Ashraf, Syeda H. Afroze, Kosei Yamauchi, David C. Zawieja, Thomas J. Kuehl, Laura Weiser Erlandson, Uddin MN. Differential Mechanism of Action of 3,4’,7-O-trimethylquercetin in Three Types of Ovarian Cancer Cells. Anticancer Res. 2018 Sep;38(9):5131-5137. doi: 10.21873/anticanres.12835.

12. Yamauchi K, Syeda H. Afroze, Mitsunaga T, T. McCormick, TJ Kuehl, DC Zawieja, Uddin MN. 3,4',7-O-trimethylquercetin Inhibits Invasion and Migration of Ovarian Cancer Cells. Anticancer Res. 2017 Jun;37(6):2823-2829.

13. K Yamauchi, T. Mitsunaga, SH Afroze Afroze, MN Uddin. Structure-Activity Relationships of Methylquercetin on Anti-migration and Anti-proliferation Activity in B16 Melanoma Cells. Anticancer Res. 2017 Apr;37(4):1575-1579.

14. J. Thomason, M. Reyes, S. R. Allen, R. O. Jones, M. R. Beeram, T.J. Kuehl, F. Suzuki, Uddin MN. Elevation of (pro)renin and (pro)renin receptor in preeclampsia. Am J Hypertens. 2015 Mar 11. pii: hpv019. [Epub ahead of print].

15. Cawyer C, Leonard D, Drever N, Jones RR, Allen SR, Beeram MR, Kuehl TJ, Uddin

MN. Hyperglycemia impedes first trimester cytotrophoblast function via apoptotic signaling.Pregnancy Hypertens. 2015 Jan;5(1):133. doi: 10.1016/j.preghy.2014.10.272. Epub 2015 Feb 23.

16. S. Lin, D. Leonard, M. A. M. Co, D. Mukhopadhyay, B. Giri, L. Perger, M. R. Beeram, T. J. Kuehl, Uddin, MN. Preeclampsia has an adverse impact on maternal and fetal health. Transl Res. 2014 Oct 16. pii: S1931-5244(14)00368-5. doi: 10.1016/j.trsl.2014.10.006. [Epub ahead of print].

17. Jessica R Ehrig, Horvat D, Leonard D, Allen SR, Jones RO, Kuehl TJ, Uddin MN. Cardiotonic steroids induce anti-angiogenic and anti-proliferative profiles in first trimester cytotrophoblast cells. Placenta. 2014 Aug 7. pii: S0143-4004(14)00641-9. doi: 10.1016/j.placenta.2014.07.014. [Epub ahead of print].

18. Chase R Cawyer, Horvat D, Leonard D, Allen SR, Jones RO, Zawieja DC, Kuehl TJ, Uddin MN. Hyperglycemia impairs cytotrophoblast function via stress signaling. Am J Obstet Gynecol. 2014 Nov;211(5):541.e1-8. doi: 10.1016/j.ajog.2014.04.033. Epub 2014 May 1.

19. Uddin MN, S. Allen, R. Jones, S.S. Glaser, D. C. Zawieja and T. J. Kuehl (2012) Pathogenesis of preeclampsia: translational aspects: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome. Transl Res. 2012 Aug; 160(2):99-113. Epub 2012 Feb 2. An invited featured article review article.

20. Puschett JB, Agunanne E, Uddin MN (2010) “Emerging role of the bufodienolides in cardiovascular and renal disease.” Am J Kidney Diseases 2010 Apr 21. [Epub ahead of print]. Review article.

21. Jules B. Puschett, Enoch Agunanne, Uddin MN (2010). “Marinobufagenin, resibufagenin and preeclampsia”. Biochim Biophys Acta. 2010 Feb 16. [Epub ahead of print]. Review article.

22. Uddin MN, Childs Ed W, Horvat D, Puschett JB (2009) “Marinobufagenin enhances endothelial permeability via activation of apoptotic signaling.” Am J Physiol Regul Integr Comp Physiol 296: R1726-R1734.

23. Uddin MN, McLean LB, Hunter FA, Horvat D, Severson J, Tharakan B, Childs EW, Puschett JB (2009) “Vascular Leak in a Rat Model of Preeclampsia.” Am J Nephrol 30: 26-33.

24. Uddin MN, Horvat D, Glaser S, Mitchell BM, Puschett JB (2008). “Examination of the cellular mechanism by which marinobufagenin inhibits cytotrophoblast function.” J. Biol. Chem. 283: 17946-17953.

25. Uddin MN, Horvat D, Glaser S, Danchuk S, Mitchell BM, Sullivan DE, Morris CA, Puschett JB (2008). “Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells.” Placenta 29(3): 266-273.